» Articles » PMID: 39763750

MCL-1 Regulates Cellular Transitions During Oligodendrocyte Development

Overview
Journal bioRxiv
Date 2025 Jan 7
PMID 39763750
Authors
Affiliations
Soon will be listed here.
Abstract

Oligodendrocytes are the myelinating cells of the central nervous system. Regulation of the early stages of oligodendrocyte development is critical to the function of the cell. Specifically, myelin sheath formation is an energetically demanding event that requires precision, as alterations may lead to dysmyelination. Recent work has established that fatty acid β-oxidation is required for the function of oligodendrocytes. We have shown that MCL-1, a well-characterized anti-apoptotic protein, is required for the development of oligodendrocytes . Further, it was recently uncovered that MCL-1 regulates long-chain fatty acid β-oxidation through its interaction with acyl-CoA synthetase long-chain family member 1 (ACSL1), an enzyme responsible for the conversion of long-chain fatty acids into acyl-CoA. Here, we introduce an system to isolate human stem cell-derived oligodendrocyte progenitor cells and investigate the involvement of MCL-1 during human oligodendrocyte development. Using this system, we pharmacologically inhibited MCL-1 in oligodendrocyte progenitor cells (OPCs) to elucidate the non-apoptotic function of the protein at this developmental stage. Additionally, we used a motor neuron co-culture system to investigate the downstream effects that MCL-1 inhibition has at later developmental stages when oligodendrocytes begin to contact axons and generate myelin basic protein. We demonstrate that the mitochondrial network changes in human oligodendrocyte development resemble those reported . Our findings point to MCL-1 as a critical factor essential at the OPC stage for proper oligodendrocyte morphogenesis.

References
1.
Hall A, Giese N, Richardson W . Spinal cord oligodendrocytes develop from ventrally derived progenitor cells that express PDGF alpha-receptors. Development. 1996; 122(12):4085-94. DOI: 10.1242/dev.122.12.4085. View

2.
Liesa M, Palacin M, Zorzano A . Mitochondrial dynamics in mammalian health and disease. Physiol Rev. 2009; 89(3):799-845. DOI: 10.1152/physrev.00030.2008. View

3.
Wang L, Owusu-Hammond C, Sievert D, Gleeson J . Stem Cell-Based Organoid Models of Neurodevelopmental Disorders. Biol Psychiatry. 2023; 93(7):622-631. PMC: 10022535. DOI: 10.1016/j.biopsych.2023.01.012. View

4.
Yin F . Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. FEBS J. 2022; 290(6):1420-1453. PMC: 9259766. DOI: 10.1111/febs.16344. View

5.
Glancy B, Kim Y, Katti P, Willingham T . The Functional Impact of Mitochondrial Structure Across Subcellular Scales. Front Physiol. 2020; 11:541040. PMC: 7686514. DOI: 10.3389/fphys.2020.541040. View